SQZ Biotechnologies (SQZ)
SQZ Biotechnologies Statistics
Share Statistics
SQZ Biotechnologies has 29.49M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 29.49M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 21.49M |
| Failed to Deliver (FTD) Shares | 22.36K |
| FTD / Avg. Volume | 4.04% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.27 and the forward PE ratio is null. SQZ Biotechnologies's PEG ratio is -0.03.
| PE Ratio | -0.27 |
| Forward PE | n/a |
| PS Ratio | 1.01 |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/FCF Ratio | -0.25 |
| PEG Ratio | -0.03 |
Enterprise Valuation
SQZ Biotechnologies has an Enterprise Value (EV) of -14.92M.
| EV / Sales | -0.71 |
| EV / EBITDA | 0.25 |
| EV / EBIT | 0.18 |
| EV / FCF | 0.18 |
Financial Position
The company has a current ratio of 3.12, with a Debt / Equity ratio of 0.48.
| Current Ratio | 3.12 |
| Quick Ratio | 3.14 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | -0.46 |
| Debt / FCF | -0.33 |
| Interest Coverage | -8.3 |
Financial Efficiency
Return on Equity is -136.91% and Return on Invested Capital is -93.89%.
| Return on Equity | -136.91% |
| Return on Assets | -78.32% |
| Return on Invested Capital | -93.89% |
| Revenue Per Employee | $396.77K |
| Profits Per Employee | $-1.48M |
| Employee Count | 53 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.22M |
| Effective Tax Rate | 1.54% |
Stock Price Statistics
The stock price has increased by 745.96% in the last 52 weeks. The beta is 2.71, so SQZ Biotechnologies's price volatility has been higher than the market average.
| Beta | 2.71 |
| 52-Week Price Change | 745.96% |
| 50-Day Moving Average | 0.15 |
| 200-Day Moving Average | 0.68 |
| Relative Strength Index (RSI) | 30.63 |
| Average Volume (20 Days) | 553.61K |
Income Statement
In the last 12 months, SQZ Biotechnologies had revenue of 21.03M and earned -78.24M in profits. Earnings per share was -2.72.
| Revenue | 21.03M |
| Gross Profit | 21.03M |
| Operating Income | -80.68M |
| Net Income | -78.24M |
| EBITDA | -59.28M |
| EBIT | -69.75M |
| Earnings Per Share (EPS) | -2.72 |
Balance Sheet
The company has 63.71M in cash and 27.47M in debt, giving a net cash position of 36.24M.
| Cash & Cash Equivalents | 63.71M |
| Total Debt | 27.47M |
| Net Cash | 36.24M |
| Retained Earnings | -274.97M |
| Total Assets | 29.79M |
| Working Capital | 3.25M |
Cash Flow
In the last 12 months, operating cash flow was -83.55M and capital expenditures -522K, giving a free cash flow of -84.07M.
| Operating Cash Flow | -83.55M |
| Capital Expenditures | -522K |
| Free Cash Flow | -84.07M |
| FCF Per Share | -2.92 |
Margins
Gross margin is 100%, with operating and profit margins of -383.68% and -372.08%.
| Gross Margin | 100% |
| Operating Margin | -383.68% |
| Pretax Margin | -377.88% |
| Profit Margin | -372.08% |
| EBITDA Margin | -281.91% |
| EBIT Margin | -383.68% |
| FCF Margin | -399.79% |
Dividends & Yields
SQZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -366.97% |
| FCF Yield | -394.3% |
Analyst Forecast
Currently there are no analyst rating for SQZ.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 7, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jul 7, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -22.94 |
| Piotroski F-Score | 2 |